| 136.93 -6.25 (-4.37%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 173.97 |
1-year : | 183.18 |
| Resists | First : | 148.94 |
Second : | 156.83 |
| Pivot price | 145.27 |
|||
| Supports | First : | 136.19 |
Second : | 113.31 |
| MAs | MA(5) : | 141.44 |
MA(20) : | 146.28 |
| MA(100) : | 138.14  |
MA(250) : | 110.56 |
|
| MACD | MACD : | -2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 22.9 |
D(3) : | 25.4 |
| RSI | RSI(14): 36.9 |
|||
| 52-week | High : | 161 | Low : | 66.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ASND ] has closed above bottom band by 6.5%. Bollinger Bands are 0.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 140.65 - 141.6 | 141.6 - 142.38 |
| Low: | 134.39 - 135.31 | 135.31 - 136.06 |
| Close: | 135.59 - 137.07 | 137.07 - 138.3 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Thu, 25 Apr 2024
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 - GlobeNewswire
Thu, 25 Apr 2024
abrdn plc Acquires Shares of 138,791 Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Thu, 25 Apr 2024
Ascendis Pharma's YORVIPATH gains UK authorization By Investing.com - Investing.com
Wed, 24 Apr 2024
Why Earnings Season Could Be Great for Ascendis Pharma (ASND) - Zacks Investment Research
Wed, 24 Apr 2024
Ascendis Pharma Gains UK Authorization for YORVIPATH - TipRanks.com - TipRanks
Wed, 24 Apr 2024
Why Earnings Season Could Be Great for Ascendis Pharma (ASND) - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 5.616e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 3,000 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.4899e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -180.6 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -29.8 % |
| Qtrly Rev. Growth | 2.6672e+008 % |
| Gross Profit (p.s.) | 983.13 |
| Sales Per Share | -1604.77 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -467 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 336.1 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | -27.18 |
| Dividend | 0 |
| Forward Dividend | 3.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|